TD Asset Management Inc Purchases 19,340 Shares of Ralliant Corporation $RAL

TD Asset Management Inc lifted its stake in shares of Ralliant Corporation (NYSE:RAL) by 9.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 232,520 shares of the company’s stock after acquiring an additional 19,340 shares during the quarter. TD Asset Management Inc’s holdings in Ralliant were worth $11,838,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Danske Bank A S bought a new stake in Ralliant in the fourth quarter worth approximately $25,000. V Square Quantitative Management LLC purchased a new position in shares of Ralliant during the fourth quarter valued at approximately $26,000. Allworth Financial LP boosted its position in shares of Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares during the last quarter. Palisade Asset Management LLC purchased a new position in shares of Ralliant during the third quarter valued at approximately $26,000. Finally, BOKF NA purchased a new position in shares of Ralliant during the third quarter valued at approximately $29,000.

Ralliant Stock Performance

NYSE:RAL opened at $61.16 on Tuesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $63.31. The firm has a market cap of $6.85 billion and a price-to-earnings ratio of -5.59. The business’s fifty day moving average is $51.16 and its 200 day moving average is $49.32.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million for the quarter. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Research analysts predict that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, June 8th. Ralliant’s payout ratio is presently -1.83%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on RAL shares. Truist Financial reaffirmed a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Oppenheimer lifted their target price on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Vertical Research cut Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a research report on Wednesday, May 27th. Finally, Citigroup lifted their target price on Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $64.50.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.